Our involvement in studies has included a mixture of Academic and Industry sponsored studies; interventional medicinal product and device studies; epidemiological and observational studies.
IN FOLLOW UP:
A new class of medication to reduce cholesterol and cardiovascular risk in people who have never had a cardiovascular event but are known to be high risk, and for whom statin treatment has not been enough or not tolerated.
Trialing a single dose Monoclonal antibody delivered intramuscularly to prevent Respiratory Syncytial Virus (RSV) in infants under the age of one year. Early results can be found here.
RSV in older adults vaccination
A trial sponsored by Glaxo Smith Kline investigating the use of a adjuvanted vaccination to prevent Respiratory Syncytial Virus (RSV) on older adults. This vaccine has now been approved for use in the EU.
A trial sponsored by Novo Nordisk trialing a new once weekly administered form of insulin. Read more about the outcomes of that trial here.
A trial sponsored by Novo Nordisk evaluating the use of semaglutide in overweight and obese adults to reduce adverse cardiovascular events. Read more about the outcomes of the trial here.
The Healum study trialed the use of personalised care plans in people with type 2 diabetes. You can read about the outcomes of the trial here.